MCID: MGR003
MIFTS: 51

Migraine with Aura

Categories: Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Migraine with Aura

MalaCards integrated aliases for Migraine with Aura:

Name: Migraine with Aura 11 5 43 14 71 33
Migraine with Typical Aura 71
Acute Migraine with Aura 33
Migraine Accompagnée 33
Complicated Migraine 33
Classical Migraine 33
Classic Migraine 11

Classifications:



External Ids:

Disease Ontology 11 DOID:10024
ICD9CM 34 346.0
MeSH 43 D020325
NCIt 49 C117005
SNOMED-CT 68 155047002
ICD10 31 G43.1
ICD11 33 525744634
UMLS 71 C0154723 C1735856

Summaries for Migraine with Aura

Disease Ontology: 11 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary: Migraine with Aura, also known as migraine with typical aura, is related to migraine, familial hemiplegic, 1 and familial hemiplegic migraine, and has symptoms including headache An important gene associated with Migraine with Aura is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Monoamine GPCRs and Synaptic vesicle pathway. The drugs Milnacipran and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are nervous system and normal

Related Diseases for Migraine with Aura

Diseases in the Migraine with Aura family:

Migraine with Aura 7 Migraine with Aura 9

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 migraine, familial hemiplegic, 1 32.8 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
2 familial hemiplegic migraine 32.7 SCN1A PRRT2 NOTCH3 KCNK18 CACNA1A ATP1A2
3 migraine, familial hemiplegic, 2 32.7 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
4 migraine, familial hemiplegic, 3 32.7 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
5 familial or sporadic hemiplegic migraine 32.6 SCN1A PRRT2 CACNA1A ATP1A2
6 migraine with or without aura 1 32.4 SLC6A4 SCN1A PRRT2 NOTCH3 MTHFR MGR1
7 headache 32.1 SLC6A4 SCN1A CACNA1A ATP1A2
8 migraine without aura 31.9 SLC6A4 SCN1A NOTCH3 MTHFR KCNK18 FHL5
9 patent foramen ovale 31.5 SCN1A NOTCH3 MTHFR FLNA EDN1 CACNA1A
10 transient cerebral ischemia 31.4 NOTCH3 MTHFR ACE
11 atrial heart septal defect 31.1 MTHFR FLNA EDN1 ACE
12 vascular disease 31.1 SLC6A4 NOTCH3 MTHFR EDN1 ACE
13 hemiplegia 31.0 SCN1A EDN1 CACNA1A ATP1A2
14 early myoclonic encephalopathy 30.9 SCN1A PRRT2 CACNA1A
15 major depressive disorder 30.9 SLC6A4 NOTCH3 HTR2C HTR1D HTR1B DRD2
16 syncope 30.9 EDN1 DBH
17 alternating hemiplegia of childhood 30.7 SCN1A PRRT2 CACNA1A ATP1A2
18 epilepsy 30.7 SCN1A PRRT2 FLNA DBH CACNA1A ATP1A2
19 epilepsy, idiopathic generalized 30.6 SCN1A PRRT2 CACNA1A ATP1A2
20 tobacco addiction 30.6 SLC6A4 MTHFR DRD2 DBH
21 generalized anxiety disorder 30.6 SLC6A4 HTR2C HTR1B DRD2
22 eclampsia 30.6 MTHFR EDN1 ACE
23 panic disorder 30.6 SLC6A4 HTR2C HTR1B DRD2 ACE
24 mood disorder 30.6 SLC6A4 HTR2C HTR1B DRD2 DBH
25 pure autonomic failure 30.5 DBH ACE
26 epilepsy, myoclonic juvenile 30.5 SCN1A PRRT2 CACNA1A
27 anxiety 30.5 SLC6A4 HTR2C HTR1D HTR1B DRD2 ACE
28 orthostatic intolerance 30.5 FLNA DBH ACE
29 bipolar disorder 30.5 SLC6A4 MTHFR HTR2C HTR1B DRD2 DBH
30 vascular dementia 30.3 NOTCH3 MTHFR ACE
31 personality disorder 30.3 SLC6A4 HTR2C HTR1D HTR1B DRD2
32 migraine with aura 7 11.6
33 migraine with aura 9 11.5
34 epilepsy, familial temporal lobe, 4 11.5
35 migraine with or without aura 13 11.2
36 familiar or sporadic hemiplegic migraine 11.2
37 brain small vessel disease 10.5 NOTCH3 KCNK18
38 central nervous system origin vertigo 10.5 MTHFR CACNA1A
39 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.5 NOTCH3 CACNA1A ATP1A2
40 trigeminal neuralgia 10.5 SLC6A4 SCN1A CACNA1A
41 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.5
42 infancy electroclinical syndrome 10.5 SCN1A PRRT2 ATP1A2
43 episodic ataxia, type 5 10.5 CACNA1A ATP1A2
44 advanced sleep phase syndrome, familial, 2 10.5 PRRT2 KCNK18
45 childhood electroclinical syndrome 10.5 SCN1A PRRT2 CACNA1A
46 torticollis 10.5 PRRT2 DRD2 CACNA1A
47 intermittent explosive disorder 10.5 SLC6A4 HTR2C DRD2
48 autonomic nervous system disease 10.5 SCN1A DBH ACE
49 brain small vessel disease 1 10.5 NOTCH3 KCNK18 CACNA1A ATP1A2
50 paine syndrome 10.5 SLC6A4 SCN1A KCNK18

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to Migraine with Aura

Symptoms & Phenotypes for Migraine with Aura

UMLS symptoms related to Migraine with Aura:


headache

MGI Mouse Phenotypes related to Migraine with Aura:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.18 ATP1A2 CACNA1A DBH DRD2 EDN1 FLNA
2 normal MP:0002873 10.1 ATP1A2 CACNA1A DBH DRD2 EDN1 FLNA
3 growth/size/body region MP:0005378 10.1 ACE ATP1A2 CACNA1A DBH DRD2 EDN1
4 muscle MP:0005369 9.97 ATP1A2 CACNA1A DRD2 EDN1 HTR1B HTR2C
5 endocrine/exocrine gland MP:0005379 9.85 ACE CACNA1A DBH DRD2 EDN1 FHL5
6 behavior/neurological MP:0005386 9.77 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
7 reproductive system MP:0005389 9.32 ACE CACNA1A DRD2 FHL5 FLNA HTR1B

Drugs & Therapeutics for Migraine with Aura

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milnacipran Approved, Investigational Phase 4 92623-85-3, 96847-54-0 11622909 65833 6917779
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Topiramate Approved Phase 4 97240-79-4 5284627
4
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
6
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
7
Almotriptan Approved, Investigational Phase 4 181183-52-8, 154323-57-6 123606
8 Psychotropic Drugs Phase 4
9 Antidepressive Agents Phase 4
10 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
11 Hypoglycemic Agents Phase 4
12 Dopamine Antagonists Phase 4
13 Antiemetics Phase 4
14 Gastrointestinal Agents Phase 4
15
Ketorolac Tromethamine Phase 4
16 Serotonin Receptor Agonists Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
19
Caffeine Approved Phase 3 58-08-2 2519
20
Eletriptan Approved, Investigational Phase 3 143322-58-1 77993
21
Rizatriptan Approved Phase 3 145202-66-0, 144034-80-0 5078
22
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
23
Angiotensin II Approved, Investigational Phase 2, Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198
24
Candesartan cilexetil Approved Phase 2, Phase 3 145040-37-5
25
Propranolol Approved, Investigational Phase 2, Phase 3 318-98-9, 525-66-6 62882 4946
26
Histamine Approved, Investigational Phase 3 51-45-6 774
27
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
28
Promethazine Approved, Investigational Phase 3 60-87-7 4927
29
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
30
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
31
Ergotamine Approved Phase 3 113-15-5 8223
32
Dihydroergotamine Approved, Investigational Phase 3 6190-39-2, 511-12-6 10531
33
Clonidine Approved Phase 3 4205-91-8, 4205-90-7 2803 20179
34
Tizanidine Approved, Investigational Phase 3 51322-75-9 5487
35
Candesartan Experimental Phase 2, Phase 3 139481-59-7 2541
36 Vasodilator Agents Phase 3
37 Central Nervous System Stimulants Phase 3
38 Phosphodiesterase Inhibitors Phase 3
39 Serotonin 5-HT1 Receptor Agonists Phase 3
40 Adrenergic beta-Antagonists Phase 2, Phase 3
41 Adrenergic Antagonists Phase 2, Phase 3
42 Anti-Arrhythmia Agents Phase 2, Phase 3
43
Angiotensinogen Phase 2, Phase 3 16133225
44 Angiotensin Receptor Antagonists Phase 2, Phase 3
45 Angiotensin II Type 1 Receptor Blockers Phase 2, Phase 3
46 Giapreza Phase 2, Phase 3
47 Anesthetics, Local Phase 3
48 Anesthetics Phase 3
49 Anti-Allergic Agents Phase 3
50
Histamine phosphate Phase 3 51-74-1 134614

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase. Completed NCT03689361 Phase 4
3 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
4 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
5 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
6 A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM) Recruiting NCT05211154 Phase 4 Diclofenac Potassium 50Mg/Pkt Oral Pwdr;Rimegepant 75 MG
7 A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM). Recruiting NCT05214001 Phase 4 Almotriptan 12.5 Mg Oral Tablet;Ubrogepant 50Mg Tab
8 Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache Completed NCT00449540 Phase 3
9 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
10 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
11 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Completed NCT03901482 Phase 3 Dihydroergotamine;Placebos
12 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
13 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Completed NCT04940390 Phase 3 Dihydroergotamine;Placebo
14 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
15 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
16 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
17 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
18 A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00131443 Phase 2, Phase 3 Topiramate
19 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
20 Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room Recruiting NCT04726592 Phase 3 Clorazepate Dipotassium;Placebo;Ketoprofen;Metoclopramide
21 An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Active, not recruiting NCT04406649 Phase 3 Dihydroergotamine
22 Safety and Efficacy of Oral Tizanidine Hydrochloride in Preventing Migraine Attacks in Adult Migraine Patients: a Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study Not yet recruiting NCT05484349 Phase 3 Tizanidine Hydrochloride;Tizanidine Hydrochloride Placebo
23 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Not yet recruiting NCT05416476 Phase 3 Anisodine Hydrobromide;Anisodine Hydrobromide placebo
24 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
25 Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura Unknown status NCT04063540 Phase 2 Amiloride;Placebos
26 A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura Unknown status NCT00877838 Phase 2 NXN-188;Placebo
27 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
28 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Placebo
29 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
30 A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura Completed NCT00920686 Phase 2 NXN-188;placebo;sumatriptan succinate
31 A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura Completed NCT00332007 Phase 2 Tonabersat;Placebo
32 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
33 An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00158002 Phase 2 Topiramate
34 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
35 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
36 Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial) Terminated NCT00505570 Phase 2
37 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
38 A Randomized, Open-Label, 5-Period Crossover Study to Evaluate the PK, Bioavailability, Safety, and Tolerability of Single Doses of STS101, DHE IM Injection and DHE Nasal Spray in Healthy Adult Subjects Completed NCT05337254 Phase 1 Dihydroergotamine
39 MR-Angiografi (MRA) og MR-Spektroskopi (MRS) Hos Raske forsøgspersoner og Patienter Med migræne Uden Aura Provokeret Med Calcitonin Gen-relateret Peptid (CGRP) og Sildenafil Unknown status NCT03143465 Calcitonin Gene-Related Peptide;Sildenafil;Placebo
40 A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura Unknown status NCT00893594 sumatriptan with naprosyn;placebo
41 The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients Unknown status NCT04452929 Erenumab;Placebo;Calcitonin gene-related peptide;Cilostazol
42 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
43 Functional MRI and MRA in Migraine With Aura Unknown status NCT01388894
44 Investigations of the Endogenous Vasoconstrictor and Neuromodulator Peptide Endothelin-1 as a Potential Trigger of Migraine Aura Unknown status NCT02906085 Endothelin-1;Placebo
45 CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls Completed NCT00687947 CGRP
46 Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura : a MRI and Transcranial Doppler. Completed NCT02708797
47 Impact of tDCS on Cerebral Autoregulation Completed NCT01865604
48 IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan Completed NCT02115269
49 Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins Completed NCT02047695
50 Study of Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries by Hypoxia in a Humane Experimental Migraine Model Completed NCT01896167

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Genetic Tests for Migraine with Aura

Anatomical Context for Migraine with Aura

Organs/tissues related to Migraine with Aura:

MalaCards : Brain, Endothelial, Cortex, Occipital Lobe, Trigeminal Ganglion, Heart, Caudate Nucleus

Publications for Migraine with Aura

Articles related to Migraine with Aura:

(show top 50) (show all 2947)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
Stroke and stroke risk factors in women of reproductive age with a history of metabolic or bariatric surgery. 62
36206629 2022
3
Vestibular Function and Clinical Presentation of Dizziness: Are They Similar in Patients With Different Types of Migraine? 62
36198653 2022
4
Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura. 62
36068697 2022
5
Evaluating the correlation between migraine and subclinical atherosclerosis. 62
36242871 2022
6
Lack of Habituation in Migraine Patients Based on High-Density EEG Analysis Using the Steady State of Visual Evoked Potential. 62
36421543 2022
7
MRI findings on a paediatric complicated migraine: left hemispheric hypoperfusion and deoxygenation. 62
36385008 2022
8
An Association Study of ESR1-XbaI and PvuII Gene Polymorphism in Migraine Susceptibility in the Jammu Region. 62
36436502 2022
9
Migraine Type-Dependent Patterns of Brain Activation After Facial and Intranasal Trigeminal Stimulation. 62
36370239 2022
10
Study of variants in genes implicated in rare familial migraine syndromes and their association with migraine in 200,000 exome-sequenced UK Biobank participants. 62
36044383 2022
11
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial. 62
36138260 2022
12
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. 62
35775208 2022
13
Development of a cluster-like headache after a stent-assisted implantation of an endovascular WEB device. 62
36379623 2022
14
Visual snow: A systematic review and a case series. 62
35945691 2022
15
Stroke-prone salt-sensitive spontaneously hypertensive rats show higher susceptibility to spreading depolarization (SD) and altered hemodynamic responses to SD. 62
36329390 2022
16
Management and behavior-modifying recommendation effects in childhood headache. 62
36326638 2022
17
E. H. Sieveking and his cephalalgia epileptica. 62
35724331 2022
18
A cross-sectional study on the association between Helicobacter pylori infection and headache. 62
35643992 2022
19
Clinical application of brain perfusion imaging in detecting stroke mimics: A review. 62
36207276 2022
20
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL): A Rare Cause of Transient Ischemic Attack. 62
36465750 2022
21
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study. 62
36195842 2022
22
Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study. 62
35633027 2022
23
Meta-analytical evidence of functional and structural abnormalities associated with pain processing in migraine patients: An activation likelihood estimation. 62
36316871 2022
24
Migraine and Current Pharmacologic Management. 62
36337819 2022
25
A systematic review and meta-analysis of voxel-based morphometric studies of migraine. 62
36098838 2022
26
The headache and aura-inducing effects of sildenafil in patients with migraine with aura. 62
35332812 2022
27
Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients. 62
35421036 2022
28
2022 Taiwan Guidelines for Preventive Treatment of Migraine. 62
36089629 2022
29
P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study. 62
35332814 2022
30
PARACENTRAL ACUTE MIDDLE MACULOPATHY IN A PATIENT WITH FREQUENT MIGRAINE WITH AURA: A CASE REPORT. 62
36001683 2022
31
Elderly CADASIL patients with intact neurological status. 62
36221938 2022
32
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men. 62
35676887 2022
33
Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study. 62
36017980 2022
34
Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists. 62
36062775 2022
35
Evidence-Based Contraception: Common Questions and Answers. 62
36126006 2022
36
Interneuronal dynamics facilitate the initiation of spike block in cortical microcircuits. 62
35441302 2022
37
The Epidemiology of Primary Headache Disorders. 62
36104164 2022
38
Headache in Children and Adolescents: The Association between Screen Time and Headache within a Clinical Headache Population. 62
34905787 2022
39
The Modifying of Functional Connectivity Induced by Peripheral Nerve Field Stimulation using Electroacupuncture for Migraine: A Prospective Clinical Study. 62
35312785 2022
40
Insular functional connectivity in migraine with aura. 62
35982396 2022
41
Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura. 62
35302383 2022
42
Cerebrovascular function in tension-type headache and migraine with or without aura: Transcranial Doppler study. 62
35982093 2022
43
Evaluation of retinal vessel and perfusion density in migraine patients by optical coherence tomography angiography. 62
35961536 2022
44
Ocular Migraine With Amaurosis Fugax of the Left Eye: A Case Report. 62
36158378 2022
45
Association between migraine and risk of stroke: a systematic review and meta-analysis. 62
35451664 2022
46
Migraine-Associated Common Genetic Variants Confer Greater Risk of Posterior vs. Anterior Circulation Ischemic Stroke☆. 62
35576861 2022
47
Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine. 62
35166151 2022
48
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks. 62
35820799 2022
49
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients. 62
35883029 2022
50
Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign. 62
35301873 2022

Variations for Migraine with Aura

ClinVar genetic disease variations for Migraine with Aura:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic
812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
2 overlap with 2 genes GRCh37/hg19 Xq28(chrX:153588672-153609996) CN GAIN Pathogenic
523301 GRCh37: X:153588672-153609996
GRCh38:
3 FLNA GRCh37/hg19 Xq28(chrX:153575976-153586768) CN LOSS Pathogenic
523300 GRCh37: X:153575976-153586768
GRCh38:
4 NOTCH3 NM_000435.3(NOTCH3):c.1162T>C (p.Cys388Arg) SNV Likely Pathogenic
812743 rs1599391938 GRCh37: 19:15300114-15300114
GRCh38: 19:15189303-15189303
5 NOTCH3 NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser) SNV Likely Pathogenic
812744 rs1599391986 GRCh37: 19:15300140-15300140
GRCh38: 19:15189329-15189329
6 DGUOK NM_080916.3(DGUOK):c.278G>A (p.Gly93Glu) SNV Uncertain Significance
523553 rs1553403624 GRCh37: 2:74173868-74173868
GRCh38: 2:73946741-73946741
7 DGUOK NM_080916.3(DGUOK):c.65C>T (p.Pro22Leu) SNV Uncertain Significance
523554 rs757962437 GRCh37: 2:74154102-74154102
GRCh38: 2:73926975-73926975

Expression for Migraine with Aura

Search GEO for disease gene expression data for Migraine with Aura.

Pathways for Migraine with Aura

GO Terms for Migraine with Aura

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.5 ACE ATP1A2 CACNA1A DBH DRD2 HTR1B
2 membrane GO:0016020 10.5 ACE ATP1A2 CACNA1A DBH DRD2 HTR1B
3 plasma membrane GO:0005886 10.43 SLC6A4 KCNK18 HTR2C HTR1D HTR1B DRD2
4 plasma membrane GO:0005887 10.43 SLC6A4 KCNK18 HTR2C HTR1D HTR1B DRD2
5 G protein-coupled serotonin receptor complex GO:0098666 9.67 HTR2C HTR1B
6 presynaptic membrane GO:0042734 9.65 SLC6A4 PRRT2 HTR1B DRD2
7 synapse GO:0045202 9.5 SLC6A4 PRRT2 MTHFR HTR2C HTR1D DRD2
8 serotonergic synapse GO:0099154 9.46 HTR1B SLC6A4
9 obsolete integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 PRRT2 HTR1B DRD2

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.13 CACNA1A DBH HTR1B HTR1D HTR2C
2 response to xenobiotic stimulus GO:0009410 10.11 SLC6A4 MTHFR EDN1 DRD2 ACE
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 10.08 HTR2C HTR1D HTR1B
4 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 10.03 EDN1 HTR1B HTR1D
5 visual learning GO:0008542 10 ATP1A2 DBH DRD2
6 release of sequestered calcium ion into cytosol GO:0051209 9.99 HTR2C FLNA DRD2
7 response to nicotine GO:0035094 9.95 EDN1 DRD2 ATP1A2
8 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.91 HTR1B DRD2
9 regulation of behavior GO:0050795 9.89 HTR1D HTR1B
10 negative regulation of cytosolic calcium ion concentration GO:0051481 9.88 DRD2 ATP1A2
11 behavioral response to ethanol GO:0048149 9.88 DRD2 DBH
12 blood vessel remodeling GO:0001974 9.88 FLNA DBH ACE
13 drinking behavior GO:0042756 9.87 HTR1B DRD2
14 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.84 HTR1D HTR1B
15 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.8 FLNA DRD2
16 response to amphetamine GO:0001975 9.8 DBH DRD2 EDN1
17 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.73 DRD2 EDN1 HTR2C
18 feeding behavior GO:0007631 9.67 HTR2C HTR1B DRD2
19 regulation of vasoconstriction GO:0019229 9.63 EDN1 ATP1A2 ACE
20 regulation of biological quality GO:0065008 9.61 EDN1 DRD2
21 response to hypoxia GO:0001666 9.61 SLC6A4 MTHFR EDN1 DRD2 ACE
22 behavior GO:0007610 9.55 HTR2C HTR1B
23 vasoconstriction GO:0042310 9.4 SLC6A4 HTR1D HTR1B EDN1 DBH ACE

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled serotonin receptor activity GO:0004993 9.63 HTR2C HTR1D HTR1B
2 heterocyclic compound binding GO:1901363 9.35 HTR1B DRD2 ACE
3 serotonin binding GO:0051378 9.23 SLC6A4 HTR2C HTR1D HTR1B

Sources for Migraine with Aura

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....